Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB)Mission will receive up to U ...

Democratic members of Congress demanded answers about Homeland Security's vetting and training of immigration enforcement ...

The mayor issued a statement in response to Adam Silver's concerns that appear to be about the pace and tenor of negotiations ...

Nature Medicine today featured on its cover the findings from The Feinstein Institutes for Medical Research, demonstrating ...

Five malicious versions of AsyncAPI packages were published to the Node Package Manager (npm) in a supply-chain attack that ...